Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe RCC (mchRCC), is limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients, in terms of outcome and comparison to mccRCC.
Records from mchRCC patients treated with first line sunitinb in 10 centers across 4 countries were retrospectively reviewed. Univariate and multivariate analyses of association between clinicopathologic factors and outcome were performed. Subsequently, mchRCC pts were individually matched to mccRCC pts. We compared the clinical benefit rate (CBR), progression free survival (PFS), and overall survival (OS) between the groups.
Between 2004-2014, 36 patients (median age 64, 47% male) with mchRCC were treated with first line sunitinib. 78% achieved a clinical benefit (partial response + stable disease). Median progression free survival (PFS) and overall survival (OS) were 10 and 26 months, respectively. Factors associated with PFS were the HENG risk (HR 3.3, p = 0.03) and pre-treatment neutrophil to lymphocyte ratio (NLR) >3 (HR 0.63, p = 0.02). Factors associated with OS were the HENG risk (HR 4.1, p = 0.04), liver metastases (HR 3.8, p = 0.03), and pre-treatment NLR
In metastatic chromophobe renal cell carcinoma, sunitinib therapy may be associated with similar outcome and toxicities as in metastatic clear cell renal cell carcinoma. The HENG risk and pre-treatment NLR may be associated with PFS and OS.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.